ArticleJournal of clinical hypertension (Greenwich, Conn.)2020
A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The effect of digital therapeutics intervention on improving hypertension management in adults: a meta-analysis of randomized controlled trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Pooled it
- Home blood pressure-lowering effect of digital therapeutics in hypertension: impact of body weight and salt intake.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Trial
- Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial.European heart journal · 2021Trial
- Digital therapeutics for essential hypertension using a smartphone application: A randomized, open-label, multicenter pilot study.Journal of clinical hypertension (Greenwich, Conn.) · 2021Trial
- Digital health technologies in medicine: evidence, artificial intelligence integration, and ethical challenges.Infectious agents and cancer · 2026Review
- Framing financial incentives to promote hypertension care among rural primary doctors in Shandong Province, China: study protocol of a randomized field trial.Health economics review · 2025Article
- Information and Communications Technology-Based Monitoring Service for Tailored Chronic Disease Management in Primary Care: Cost-Effectiveness Analysis Based on ICT-CM Trial Results.Journal of medical Internet research · 2024Article
- Exploring the Feasibility and Initial Impact of an mHealth-Based Disease Management Program for Chronic Ischemic Heart Disease: Formative Study.JMIR formative research · 2024Article
- Adoption of Digital Therapeutics in Europe.Therapeutics and clinical risk management · 2024Review
- Digital hypertension towards to the anticipation medicine.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Review
- Cost-effectiveness of digital therapeutics for essential hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Home Blood Pressure Monitoring: Current Status and New Developments.American journal of hypertension · 2021Article
- A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial.Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital therapeutics is a new approach to treat hypertension via using software programs such as smartphone apps and/or device algorithms. We develop a HERB system-new interactive smartphone app (HERB Mobile) with web-based patient management console (HERB Console)-to lower blood pressure (BP) based on an algorithm that helps users to promote lifestyle modifications in conjunction with medically validated non-pharmacological interventions. The app can assess the personalities, behavior characteristics, and hypertension determinants of each patient with hypertension to provide adequate guidance. To demonstrate the efficacy of the system, we designed a randomized, controlled, multicenter, open-label trial "HERB-DH1 (HERB digital hypertension 1)" to assess the efficacy of HERB system in patients with essential hypertension. The authors allocate patients to the intervention group (HERB system + standard lifestyle modification) or to the control group (standard lifestyle modification alone). In the intervention group, we provide the HERB Mobile for patients and the HERB Console for their primary physicians for 24 weeks. Both groups are instructed for standard lifestyle modifications based on the current recommendations in the Japanese Society of Hypertension 2019 guideline. The primary outcome is the mean change from baseline to 12 weeks in 24-hour systolic BP measured by ambulatory BP monitoring. We started this study in December of 2019, and the trial results will be expected in early 2021. We believe that this trial enables us to verify the efficacy of the HERB system in patients with essential hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.